Inactive

NCATS seeks to determine if YC1 which works with a unique mechanism of cytotoxicity towards cancer cells that express SULT1A1. In doing so, NCATS shall establish the therapeutic window for YC1. To tha... NCATS seeks to determine if YC1 which works with a unique mechanism of cytotoxicity towards cancer cells that express SULT1A1. In doing so, NCATS shall establish the therapeutic window for YC1. To that end NCATS requires head-to-head comparison on YC1 in mice that have humanized SULT1A1 (custom mice available at GemPharmaTech) and with mouse SULT1A1 (wild type).